北米の急性リンパ性/リンパ芽球性白血病（ALL）診断市場
Market Size in USD Billion
CAGR :
% 
 予測期間 |
2024 –2030 |
 市場規模（基準年） |
|
 Market Size (Forecast Year) |
USD 979.89 |
 CAGR |
% |
| 主要市場プレーヤー |
>北米の急性リンパ性/リンパ芽球性白血病 (ALL) 診断市場、製品タイプ別 (機器および消耗品と付属品)、検査タイプ別 (画像検査、生検、血液検査、その他)、がんタイプ別 (B 細胞リンパ芽球性白血病/リンパ腫、T 細胞リンパ芽球性白血病)、年齢グループ別 (21 歳未満、21 ～ 29 歳、30 ～ 65 歳、65 歳以上)、性別別 (男性と女性)、エンドユーザー別 (病院、関連研究所、独立診断研究所、診断画像センター、がん研究機関、その他)、流通チャネル別 (直接入札、小売販売) 業界動向と 2030 年までの予測。
北米の急性リンパ性/リンパ芽球性白血病（ALL）診断市場の分析と洞察
血液がんは、ここ数十年、世界中で最も一般的ながんです。がんの発生率は、男女ともに上昇傾向にあります。男性の方が女性よりわずかに多く発生します。急性リンパ性白血病 (ALL) は、米国のリンパ系腫瘍の約 2% を占めています。患者は通常、骨髄が腫瘍に置き換わることによって、貧血、血小板減少症、好中球減少症に関連する症状を呈します。白血病の診断治療における激しい競争と、世界中で診断の改善が求められていることから、この分野ではさまざまなサービスの需要が高まっています。さまざまな企業が、北米の急性リンパ性/リンパ芽球性白血病 (ALL) 診断市場に対する世界的な需要の高まりに対応するために、多数の診断製品を発売しています。
しかし、白血病の治療には、治療法、医薬品などを含めて高額な費用がかかることが、最も重要な要因の 1 つです。その結果、長期的には市場の成長が阻害される可能性があります。診断製品のコストは、白血病診断装置ベンダーにとって課題となる可能性のある要素の 1 つです。
Data Bridge Market Research の分析によると、北米の急性リンパ性/リンパ芽球性白血病 (ALL) 診断市場は、予測期間中に 7.6% の CAGR で成長し、2030 年までに 9 億 7,989 万米ドルに達する見込みです。北米では白血病診断の需要が急増しているため、製品タイプが市場で最大のセグメントを占めています。この市場レポートでは、価格分析、特許分析、技術進歩についても詳細に取り上げています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2023年から2030年 |
|
基準年 |
2022 |
|
歴史的な年 |
2021 (2020～2016年にカスタマイズ可能) |
|
定量単位 |
売上高（百万米ドル）、販売数量（個数）、価格（米ドル） |
|
対象セグメント |
By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (B-cell Lymphoblastic Leukemia/Lymphoma, and T-cell Lymphoblastic Leukemia), Age Group (Below 21, 21-29, 30-65, 65 and Above), Gender (Male and Female) End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales) |
|
Countries Covered |
U.S., Canada, and Mexico. |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN, Abbott, Siemens Medical Solutions USA, Inc., Merck KGaA, Hologic, Inc., Agilent Technologies, Inc., DiaSorin S.p.A., Illumina, Inc., Myriad Genetics, Inc., Quest Diagnostics Incorporated., Bio-Rad Laboratories, Inc., Koninklijke Philips N.V., BD, Exact Sciences Corporation, Time Medical Holding, Michelson Diagnostics Ltd., MinFound Medical Systems Co., Ltd among others |
Market Definition
Acute lymphocytic leukemia (ALL) is a malignancy of B or T-lymphoblasts characterized by uncontrolled proliferation of abnormal, immature lymphocytes and their progenitors, which ultimately leads to the replacement of bone marrow elements and other lymphoid organs resulting in a characteristic disease pattern. B-cells are a specific type of lymph cell that affect a body's immune system. Two types of B-cell leukemia are prolymphocytic leukemia (PLL) and Hairy Cell Leukemia (HCL). Symptoms include fatigue, easy or spontaneous bruising and bleeding, and infections. Additionally, B-symptoms, such as fever, night sweats, and unintentional weight loss, are often present but may be mild, and hepatomegaly, splenomegaly, and lymphadenopathy can be seen in up to half of adults on presentation. Central Nervous System (CNS) involvement is common and can be accompanied by cranial neuropathies or symptoms, predominantly meningeal, related to increased intracranial pressure. T-cell lymphoblastic leukemia is most common among children aged over five years. The increasing cases of cancer worldwide and the rising prevalence of lymphoblastic leukemia are expected to drive segmental T-cell acute lymphoblastic leukemia market growth. These white blood cell acutely influences white platelets called T- lymphocytes. The North America acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is expected to show significant growth due to the rising prevalence of T-cell acute lymphoblastic leukemia, research and development activities, and high healthcare expenditure.
North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Growing prevalence of leukemia cancer
All ages can be affected by leukemia. Leukemia can be difficult to diagnose because, despite its wide range of signs and symptoms, they are non-specific and can be linked to other, more widespread medical conditions. Acute lymphoblastic leukemia has the highest emergency presenting rates of any cancer kind, with a leukemia emergency diagnostic rate of 37% on average.
The most frequent form of juvenile cancer is acute lymphoblastic leukemia, a heterogeneous illness defined by unchecked lymphoid progenitor proliferation that typically begins in utero. Although the prevalence of ALL has been rising significantly in recent decades, there is still no apparent cause for this development. Rising maternal obesity rates may be partially responsible for the rise in ALL prevalence.
Thus, acute leukemia incidence has been rising North America due to various risk factors, becoming a significant socio-economic issue. This is expected to act as a driver in the North America acute lymphocytic\lymphoblastic leukemia (ALL) diagnostics market.
- Novel technological advancements in leukemia diagnostics
The most common form of blood cancer, acute lymphoblastic leukemia (ALL), is also one of the main causes of death. The blood is invaded by this form of cancer, which then spreads to nearby organs and bodily systems. Specialists must manually diagnose cancer and non-cancer cells by examining cell images under a microscope and providing labels through annotation. However, this hand microscopic examination is time-consuming and could give an incorrect diagnosis.
The risk of prescribing the incorrect drugs was then reduced using computerized software. The creation of an automatic and reliable classification system became vital to stop the leukemia disease's devastating effects. Multiple segmentation techniques constituted the foundation of the existing leukemia classification algorithms.
The manual examination of stained blood smear microscopy pictures used in current practice for the initial diagnosis of ALL is time-consuming and prone to error. A potent tool for aiding doctors in making medical decisions has emerged: deep learning-based human-centric biomedical diagnostics. Various computer-aided diagnostic techniques have been created to recognize ALL blood pictures automatically.
The development of several new diagnostic methods will increase the market's growth as many new and advanced products are launched. Hence, it is expected to create demand for acute leukemic cancer diagnosis in the North America acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.
Restraint
- Late diagnosis and poor prognosis of leukemia
Cancer is the leading cause of death North America. By 2030, it is anticipated that there will be 13.1 million more cancer-related deaths per year. However, if they are identified early on and given the right care, some cancers can be cured. The diagnostic process may experience delays in cancer diagnosis. When patients overlook or fail to respond to potentially cancerous signs, patient delays may result. The main cause of delayed presentation is thought to be a lack of public knowledge of early cancer signs, especially if such symptoms are unusual.
The late diagnosis often results from these factors, which result in poor prognosis. Thus, these are expected to restrain the growth of the North America acute lymphocytic\lymphoblastic leukemia (ALL) diagnostics market.
Opportunities
- Increase in diagnostic products for leukemia
A blood-forming tissue cancer impairs the body's capability to combat infection. Bone marrow is one of the blood-forming tissues that can develop leukemia. Numerous varieties include chronic lymphocytic leukemia, acute myeloid leukemia, and acute lymphoblastic leukemia. Many patients with leukemia that grow slowly do not exhibit any symptoms. Fatigue, weight loss, recurrent infections, and easy bruising or bleeding are all possible symptoms of leukemia that grow quickly. Treatment results vary greatly. Treatment for leukemia with a slow growth rate may involve monitoring. Chemotherapy for malignant leukemia is occasionally combined with radiation therapy and stem cell transplant.
Thus, the rise in diagnostic product approvals has led to an increased number of highly efficient products in the market for leukemia diagnosis treatment. This is expected to create an opportunity for the North America acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.
- Government initiatives toward cancer diagnostics
The government plays a major role while taking the initiative for cancer diseases because cancer is a leading disease worldwide. Leukemia has increased very rapidly in individuals in past decades. Leukemia is the most prevalent cancer, with 60,650 new cases in 2022, according to cancer.gov.
There are several initiatives taken by the government that helps boost the market's demand, and these initiatives will increase awareness among people regarding their health and take early diagnosis for better cure and precaution. For this reason, government initiatives towards cancer diagnostics are acting as an opportunity for growing the demand of the North America acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.
Challenge
- Increased cost, safety, and convenience issue
Leukemia is fatal cancer, and the diagnosis process of leukemia also has safety issues; it is not cost-effective. One of the most costly medical disorders to treat North America is cancer. Cancer patients may be hospitalized and receive a variety of therapies, such as surgery, radiation therapy, and systemic therapy. Health insurance premiums for cancer patients are now more expensive than in the past. In addition, their copayment, deductible, and coinsurance costs are rising.
Rising helium shortage and rising risk of excessive radiation exposure are projected to restrict the use of CT scanners, threatening the possibilities of rising capital investments and low benefit-cost ratio for biomarkers. Many hospitals in developing countries cannot invest in diagnostic imaging equipment, which has led to an increase in the use of reconstructed diagnostic imaging due to high expenditures and financial restrictions. Due to the increasing demand for diagnostic imaging operations in these nations, hospitals that can't afford to buy new, cutting-edge imaging systems instead choose to employ refurbished imaging equipment, which could have long-term negative effects.
Henceforth, the current leukemia diagnosis process has safety, cost, and convenience issues, which are expected to challenge the growth of the North America acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.
Post-COVID-19 Impact on North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market
The cancer diagnostics market has been badly affected by COVID-19. Hospital admissions were limited to non-essential treatment, and clinics were temporarily closed during the pandemic. The implementation of social distancing, blocking the population, and limited access to clinics have greatly affected the market. The slowdown in patient flows and referrals also affected the market growth. However, the market will continue to grow in the post-pandemic period due to the relaxation of previously imposed restrictions.
Manufacturers make various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results in the cancer diagnostics market.
Recent Developments
- In October 2022, Thermo Fisher Scientific Inc. announced that it had entered into a definitive agreement to acquire The Binding Site Group, a North America leader in specialty diagnostics. The acquisition will help in the development of the specialty diagnostics segment.
- In August 2022, F. Hoffmann-La Roche Ltd. announced the launch of a Digital LightCycler System. This next-generation digital PCR system helps clinical researchers better understand the nature of a patient's cancer, genetic disease, or infection. This system is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in oncology and infectious diseases.
North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market Scope
The North America acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into product type, test type, cancer type, age group, gender, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Product Type
- Instruments
- Consumables & Accessories
On the basis of product type, the North America acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into instruments, consumables & accessories.
Test Type
- Imaging Test
- Biopsy
- Blood Test
- Others
On the basis of test type, the North America acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into imaging test, biopsy, blood test, and others.
Cancer Type
- B-cell Lymphoblastic Leukemia /Lymphoma
- T-cell Lymphoblastic Leukemia
On the basis of cancer type, the North America acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into B-cell lymphoblastic leukemia/lymphoma and T-cell lymphoblastic leukemia.
By Age Group
- Below 21
- 21-29
- 30-65
- 65 and Above
On the basis of age group, the North America acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into below 21, 21-29, 30-65, 65 and above.
By Gender
- Male
- Female
On the basis of gender, the North America acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into male and female.
By End User
- Hospital
- Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Others
On the basis of end user, the North America acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into hospital, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.
By Distribution Channel
- Direct Tender
- Retail Sales
On the basis of distribution channel, the North America acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into direct tender and retail sales.
North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market Regional Analysis/Insights
The North America acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is analyzed, and market size information is provided by country, product type, test type, cancer type, age group, gender, end user, and distribution channel.
Some countries covered in the North America acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market are the U.S., Canada, and Mexico.
The U.S is expected to grow due to the rising government initiatives in leukemia diagnostics in the North America acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個々の市場影響要因と国内規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、個々の国の市場シナリオを予測するために使用される主要な指標の一部です。また、北米ブランドの存在と入手可能性、地元および国内ブランドとの競争が激しいか少ないために直面する課題、販売チャネルの影響を考慮しながら、国別データの予測分析を提供します。
競争環境と北米の急性リンパ性/リンパ芽球性白血病（ALL）診断市場シェア分析
北米の急性リンパ性/リンパ芽球性白血病 (ALL) 診断市場の競争状況では、競合他社の詳細が提供されます。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品の承認、特許、製品の幅と広さ、アプリケーションの優位性、および技術ライフライン曲線があります。提供されている上記のデータ ポイントは、北米の急性リンパ性/リンパ芽球性白血病 (ALL) 診断市場への会社の重点にのみ関連しています。
北米の急性リンパ性/リンパ芽球性白血病（ALL）診断市場で活動している主要企業には、F. Hoffmann-La Roche Ltd.、Thermo Fisher Scientific, Inc.、QIAGEN、Abbott、Siemens Medical Solutions USA, Inc.、Merck KGaA、Hologic, Inc.、Agilent Technologies, Inc.、DiaSorin SpA、Illumina, Inc.、Myriad Genetics, Inc.、Quest Diagnostics Incorporated.、Bio-Rad Laboratories, Inc.、Koninklijke Philips NV、BD、Exact Sciences Corporation、Time Medical Holding、Michelson Diagnostics Ltd.、MinFound Medical Systems Co., Ltd などがあります。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 INDUSTRY INSIGHTS
5 EPIDEMIOLOGY
6 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS
7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
7.1.3 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER
7.1.4 GROWING PREVALENCE OF LEUKEMIA CANCER
7.2 RESTRAINTS
7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS
7.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA
7.3 OPPORTUNITIES
7.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA
7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
7.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS
7.4 CHALLENGES
7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES
7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
8 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.2.1 BIOPSY INSTRUMENTS
8.2.1.1 BONE MARROW BIOPSY
8.2.1.2 NEEDLE BIOPSY
8.2.1.3 SURGEON BIOPSY
8.2.1.4 OTHERS
8.2.2 PATHOLOGY-BASED INSTRUMENTS
8.2.2.1 PCR INSTRUMENTS
8.2.2.2 SLIDE STAINING SYSTEMS
8.2.2.3 TISSUE PROCESSING SYSTEMS
8.2.2.4 CELL PROCESSORS
8.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS
8.2.3 IMAGING INSTRUMENTS
8.2.3.1 ULTRASOUND SYSTEMS
8.2.3.2 CT SYSTEMS
8.2.3.3 MRI SYSTEMS
8.2.3.4 OTHERS
8.2.4 OTHERS
8.3 CONSUMABLES & ACCESSORIES
8.3.1 KITS
8.3.1.1 PCR KITS
8.3.1.2 DNA POLYMERASE KITS
8.3.1.3 NUCLEIC ACID ISOLATION KITS
8.3.1.4 OTHERS
8.3.2 REAGENTS
8.3.2.1 ASSAYS
8.3.2.2 BUFFERS
8.3.2.3 PRIMERS
8.3.2.4 OTHERS
8.3.3 PROBES
8.3.4 OTHER CONSUMABLES
9 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 BIOPSY
9.2.1 BONE MARROW BIOPSY
9.2.2 NEEDLE BIOPSY
9.2.3 SURGEON BIOPSY
9.2.4 OTHERS
9.3 BLOOD TEST
9.3.1 BLOOD CHEMISTRY TESTS
9.3.2 COMPLETE BLOOD COUNT (CBC)
9.3.3 OTHERS
9.4 IMAGING TEST
9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN
9.4.2 MRI
9.4.3 POSITRON EMISSION TOMOHRAPHY (PET) SCAN
9.4.4 OTHERS
9.5 OTHERS
10 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
10.2.1 EARLY PRE-B ALL
10.2.2 COMMON ALL
10.2.3 PRE-B ALL
10.2.4 MATURE B-CELL ALL
10.3 T-CELL LYMPHOBLASTIC LEUKEMIA
10.3.1 PRE-T ALL
10.3.2 MATURE T-CELL ALL
11 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 BELOW 21
11.3 21-29
11.4 30-65
11.5 65 AND ABOVE
12 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER
12.1 OVERVIEW
12.2 MALE
12.3 FEMALE
13 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 ASSOCIATED LABS
13.4 INDEPENDENT DIAGNOSTIC LABORATORIES
13.5 DIAGNOSTIC IMAGING CENTERS
13.6 CANCER RESEARCH INSTITUTES
13.7 OTHERS
14 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 RETAIL SALES
15 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION
15.1 NORTH AMERICA
15.1.1 U.S.
15.1.2 CANADA
15.1.3 MEXICO
16 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
17 SWOT ANALYSIS
18 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET
18.1 F. HOFFMANN-LA ROCHE LTD.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENT
18.2 THERMO FISHER SCIENTIFIC INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 QIAGEN
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 ABBOTT
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 SIEMENS MEDICAL SOLUTIONS USA, INC.
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.6 MERCK KGAA
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.7 HOLOGIC INC.
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 AGILENT TECHNOLOGIES, INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENT
18.9 BD
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 BIOMÉRIEUX SA
18.10.1 COMPANY SNAPSHOT
18.10.2 REVENUE ANALYSIS
18.10.3 PRODUCT PORTFOLIO
18.10.4 RECENT DEVELOPMENTS
18.11 BIO-RAD LABORATORIES, INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENT
18.12 DIASORIN S.P.A.
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS
18.13 EXACT SCIENCE CORPORATION
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENT
18.14 ILLUMINA, INC.
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENT
18.15 KONINKLIJKE PHILIPS N.V.
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENT
18.16 MEDONICA CO. LTD
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENT
18.17 MICHAEL DIAGNOSTICS LTD
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENT
18.18 MINFOUND MEDICAL SYSTEMS CO., LTD
18.18.1 COMPANY SNAPSHOT
18.18.2 PRODUCT PORTFOLIO
18.18.3 RECENT DEVELOPMENT
18.19 MYRIAD GENETICS, INC.
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENT
18.2 PLEXBIO
18.20.1 COMPANY SNAPSHOT
18.20.2 PRODUCT PORTFOLIO
18.20.3 RECENT DEVELOPMENTS
18.21 QUEST DIAGNOSTICS INCORPORATED
18.21.1 COMPANY SNAPSHOT
18.21.2 REVENUE ANALYSIS
18.21.3 PRODUCT PORTFOLIO
18.21.4 RECENT DEVELOPMENTS
18.22 STERNMED GMBH
18.22.1 COMPANY SNAPSHOT
18.22.2 PRODUCT PORTFOLIO
18.22.3 RECENT DEVELOPMENTS
18.23 TIME MEDICAL HOLDING
18.23.1 COMPANY SNAPSHOT
18.23.2 PRODUCT PORTFOLIO
18.23.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
表のリスト
TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA
TABLE 2 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA OTHERS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA BELOW 21 IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA 21-29 IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA 30-65 IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA 65 AND ABOVE IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA MALE IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA FEMALE IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA HOSPITALS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA ASSOCIATED LABS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA DIAGNOSTIC IMAGING CENTER IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA CANCER RESEARCH INSTITUTES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA OTHERS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA DIRECT TENDER IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA RETAIL SALES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 61 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 62 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 63 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 64 U.S. INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 65 U.S. PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 66 U.S. IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 67 U.S. BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 68 U.S. CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 69 U.S. KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 70 U.S. REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 71 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 72 U.S. IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 73 U.S. BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 U.S. BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 75 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 76 U.S. B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 77 U.S. T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 78 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 79 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 80 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 81 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 82 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 83 CANADA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 84 CANADA PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 85 CANADA IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 86 CANADA BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 87 CANADA CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 88 CANADA KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 89 CANADA REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 90 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 91 CANADA IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 92 CANADA BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 93 CANADA BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 94 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 95 CANADA B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 96 CANADA T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 97 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 98 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 99 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 100 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 101 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 102 MEXICO INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 103 MEXICO PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 104 MEXICO IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 105 MEXICO BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 106 MEXICO CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 107 MEXICO KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 108 MEXICO REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 109 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 110 MEXICO IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 111 MEXICO BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 112 MEXICO BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 113 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 114 MEXICO B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 115 MEXICO T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 116 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 117 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 118 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 119 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
図表一覧
FIGURE 1 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 INCREASE IN THE AWARENESS ABOUT LEUKEMIA IS EXPECTED TO DRIVE THE NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET IN THE FORECAST PERIOD
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA ACUTE LYMPHOCYTIC/ LYMPHOBLASTIC (ALL) LEUKEMIA DIAGNOSTICS MARKET
FIGURE 14 NORTH AMERICA LEUKEMIA INCIDENCE (BOTH SEXES)
FIGURE 15 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE (BOTH SEXES)
FIGURE 16 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 17 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 18 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 19 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET : BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 21 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 22 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 23 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 24 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 25 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 26 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 27 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 28 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, 2022
FIGURE 29 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 30 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 31 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 32 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY GENDER, 2022
FIGURE 33 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)
FIGURE 34 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 35 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET : BY GENDER, LIFELINE CURVE
FIGURE 36 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 37 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 38 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 39 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 41 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 42 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 43 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 45 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 46 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 47 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 48 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)
FIGURE 49 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
